TickerFacts.

Viridian Therapeutics, Inc. (VRDN): Cash & Equivalents

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2016-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest Cash & Equivalents is for the year ended 2018-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$32.61M
As of 2018-12-31
$47.44M2014-12-31: $5.12M2015-12-31: $10.83M2016-12-31: $22.10M2017-12-31: $47.44M2018-12-31: $32.61M$32.61M
2014-12-31 Cash & Equivalents (USD) 2018-12-31
Period endedCash & EquivalentsChange YoYSource filing
2018-12-31$32.61M-31.3%2019-03-14, Balance as of period end
2017-12-31$47.44M+114.6%2019-03-14, Balance as of period end
2016-12-31$22.10Mn/c2018-03-15, Balance as of period end
2015-12-31$10.83M+111.6%2017-03-24, Balance as of period end
2014-12-31$5.12Mn/a2016-03-21, Balance as of period end